Evidence map›Paper›PMID 42696492›Full record

ArticleRespiration; international review of thoracic diseases2026

Tidal Volume in Idiopathic Pulmonary Fibrosis: Restriction Severity and Prognostic Information beyond Forced Vital Capacity.

Ekaterina Krauss, Silke Tello, Til K Spreuer, Katharina Wendlandt, Ayca Tunay, Poornima Mahavadi, Carlo Vancheri, Maria Molina Molina, Bruno Crestani, Andreas Günther

Abstract read
In one paragraph

Article in Respiration; international review of thoracic diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ekaterina KraussEuropean IPF/ILD Registry and Biobank (eurIPFreg/bank, eurILDreg/bank), Giessen, Germany.
Silke TelloEuropean IPF/ILD Registry and Biobank (eurIPFreg/bank, eurILDreg/bank), Giessen, Germany.
Til K SpreuerEuropean IPF/ILD Registry and Biobank (eurIPFreg/bank, eurILDreg/bank), Giessen, Germany.
Katharina WendlandtEuropean IPF/ILD Registry and Biobank (eurIPFreg/bank, eurILDreg/bank), Giessen, Germany.
Ayca TunayEuropean IPF/ILD Registry and Biobank (eurIPFreg/bank, eurILDreg/bank), Giessen, Germany.
Poornima MahavadiEuropean IPF/ILD Registry and Biobank (eurIPFreg/bank, eurILDreg/bank), Giessen, Germany.
Carlo VancheriEuropean IPF/ILD Registry and Biobank (eurIPFreg/bank, eurILDreg/bank), Giessen, Germany.
Maria Molina MolinaEuropean IPF/ILD Registry and Biobank (eurIPFreg/bank, eurILDreg/bank), Giessen, Germany.
Bruno CrestaniEuropean IPF/ILD Registry and Biobank (eurIPFreg/bank, eurILDreg/bank), Giessen, Germany.
Andreas GüntherEuropean IPF/ILD Registry and Biobank (eurIPFreg/bank, eurILDreg/bank), Giessen, Germany, andreas.guenther@innere.med.uni-giessen.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionIdiopathic pulmonary fibrosis (IPF) is characterised by progressive loss of lung compliance, which raises the elastic work of breathing and alters resting ventilatory strategy. Clinical assessment of IPF still relies on forced manoeuvres, particularly forced vital capacity (FVC), which capture maximal performance rather than this resting adaptation. How tidal volume (VT) evolves over the IPF course is not well characterised. VT and the VT/FVC ratio offer an effort-independent window onto the same physiology, characterised here longitudinally.

methodsWe analysed 613 IPF patients enrolled at 3 European eurIPFreg centres (Giessen, Barcelona, Paris) between 2009 and 2025. Baseline VT, FVC, and VT/FVC were compared between survivors and non-survivors. Transplant-free survival was analysed by Cox regression, including age, sex, antifibrotic treatment, log-transformed VT and FVC, and their interaction. Discrimination was assessed by Harrell's C index with 20-fold cross-validation and time-dependent AUCs. Longitudinal trajectories were modeled over 60 months.

resultsVT followed a dynamic, non-monotonic trajectory consistent with progressive ventilatory adaptation, rising transiently to ∼5% above baseline at months 18-21, coincident with the steepest segment of FVC decline (months: 6-18), and returning slowly toward baseline thereafter. The VT/FVC ratio rose continuously (+17% at 60 months), the only marker to evolve monotonically, while FVC declined progressively (-8.8%). Higher baseline VT showed a trend toward improved survival (log-rank p = 0.092; hazard ratio [HR]: 0.88, 95% CI: 0.75-1.04), and the VT/FVC ratio stratified survival significantly (log-rank p < 0.001), as did baseline FVC (HR: 0.59 per unit log-FVC, 95% CI: 0.49-0.69; p < 0.001). The VT × FVC interaction approached significance (HR: 1.12, 95% CI: 0.98-1.30; p = 0.08), suggesting a joint physiological signal. Antifibrotic therapy reduced mortality (HR: 0.63, 95% CI: 0.50-0.81; p < 0.001).

conclusionVT in IPF follows a dynamic, non-monotonic course, rising during the steepest phase of FVC decline and returning toward baseline thereafter, consistent with a ventilatory adaptation in which increased VT serves as a transient lower cost strategy for maintaining minute ventilation before the elastic load makes it unsustainable. The VT/FVC ratio integrates this rising drive with falling vital capacity, evolves monotonically, and stratifies survival, identifying it as an effort-independent physiological descriptor of restrictive remodelling. Together, VT and VT/FVC enrich the standard FVC-based assessment of IPF by capturing the resting ventilatory dimension of disease progression.

Indexed as

European registry for idiopathic pulmonary fibrosisEuropean registry for interstitial lung diseasesIdiopathic pulmonary fibrosisTidal breathingTidal volume

Identifiers

PMID42696492
PMCPMC13592791

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.